Search results for " mammalian" in Articles / App Notes
Article
A Closer Look at Affinity Ligands
Large-scale manufacturing of a therapeutic monoclonal antibody (mAb) starts with the expression of the antibody in mammalian cells, typically CHO [Chinese hamster ovary] cells, followed by a series of…
Article
Maximum Output Starts with Optimized Upstream Processing
…zation of current biologics manufacturing capacity, says Jeetendra Vaghjiani, director of commercial mammalian development at Lonza. Overall, though, he notes that COVID-19-related projects including…
Article
Commercial Production of Gene Therapies Using Suspension or Adherent Cell Lines
This article will explore the traditional path from the laboratory to the clinic and how the fixed-bed technology provides an alternative solution to meet commercial demands.
By Alex Chatel and …
Article
Virus-like Particles as Therapeutic Moieties of the Future
At least 110 VLPs have been constructed so far from 30 different virus families (1), and a variety of expression systems ranging from bacteria to mammalian cell systems have been used for their produc…
Article
Gene Therapies Push Viral Vector Production
That being said, other technologies such mRNAs delivered to the target cells with, for example, mammalian cell-line produced engineered exosomes, start to show their capabilities,” Touw interjects. “A…
Article
Best Practices for Selecting a Top-Quality Cell Line
…nts), unique epigenetic DNA-based elements that control the dynamic organization of chromatin in all mammalian cells and allow for higher and more stable expression of recombinant proteins.
A …
Article
What’s New in Upstream Technologies
“Optimized mammalian processes are yielding higher cell densities and more product than ever,” said Cristy Botens, product manager of Bioprocessing, Distek, in a March 21, 2019 company press release. …
Article
Real-Time Characterization of Biotherapeutics and Comparability of Biosimilars
Because nearly all mAb biosimilars are produced in mammalian cells, they exhibit different post translational modifications (PTMs), which results in heterogeneity. This could be attributed to differen…
Article
Advances in Engineering of Protein-Based APIs
“The latter is a fully mammalian technology that generates in-vitro antibody diversity through ex-vivo V(D)J recombination in cultured cells. These technologies enhance both the speed and success of d…
Article
A Plastic Pipeline for Commercial Bioprocessing?
Jenifer Wheat, head of commercial development, mammalian and microbial manufacturing business unit, Lonza Pharma & Biotech, says, “There’s enough room for all the scales out there. It’s not going to b…